)
Radiopharm Theranostics (RAD) investor relations material
Radiopharm Theranostics Investor Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Clinical pipeline and trial progress
Six clinical-stage programs targeting brain metastases, pancreatic cancer, HER2+ and PD-L1+ solid tumors, B7-H3, and KLK3, with two diagnostics and four therapeutics in trials by December 2025.
Phase 2b imaging study for brain metastases (RAD101) is ongoing, with 12/30 patients dosed and completion expected in Q1 2026; early data show increased metabolic activity in suspected relapses.
Phase 1 trials for HER2+ (RAD202) and PD-L1+ (RAD204) solid tumors are enrolling, with favorable safety profiles and early signs of disease stabilization in heavily pretreated patients.
Phase 1 imaging trial for pancreatic cancer (RAD301) is ongoing, with high sensitivity for detecting primary and metastatic lesions; 6/9 patients dosed as of October 2025.
Commercial potential and market positioning
RAD101 is projected to reach over $500 million in annual US sales, with a peak market share of 94% by year 8, targeting a large unmet need in post-SRS brain metastasis imaging.
No direct competitors identified for RAD101 in brain metastasis PET imaging; other pipeline assets address multi-billion dollar markets in HER2+ and PD-L1+ cancers.
Strategic partnership with Lantheus includes a 12% equity stake and co-development agreement, with Lantheus funding clinical development costs.
Financials and capital raising
Approximately A$40 million is being raised via a two-tranche placement and share purchase plan at A$0.03 per share, an 18.9% discount to the last close.
Post-raise, pro forma cash balance is expected to be A$59 million, fully funding clinical programs through multiple near-term catalysts and into 2027.
Lantheus committed to participate for US$5 million (A$7.6 million); Bell Potter, Leerink Partners, and B. Riley Securities are managing the offer.
Next Radiopharm Theranostics earnings date
Next Radiopharm Theranostics earnings date
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)